+

PE20181090A1 - Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 - Google Patents

Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38

Info

Publication number
PE20181090A1
PE20181090A1 PE2017002833A PE2017002833A PE20181090A1 PE 20181090 A1 PE20181090 A1 PE 20181090A1 PE 2017002833 A PE2017002833 A PE 2017002833A PE 2017002833 A PE2017002833 A PE 2017002833A PE 20181090 A1 PE20181090 A1 PE 20181090A1
Authority
PE
Peru
Prior art keywords
num
sec
ident
antibodies
treatment
Prior art date
Application number
PE2017002833A
Other languages
English (en)
Inventor
Tineke Casneuf
Henk M Lokhorst
Tuna Mutis
Tahamtan Ahmadi
Amy Sasser
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20181090A1 publication Critical patent/PE20181090A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a metodos para la inmunomodulacion con anticuerpos que se unen especificamente a CD38, caracterizado porque el anticuerpo comprende la HCDR1, la HCDR2, la HCDR3, la LCDR1, la LCDR2 y la LCDR3 de: a) la VH de la sec. con num. de ident.: 14 y la VL de la sec. con num. de ident.: 15; b) la VH de la sec. con num. de ident.: 16 y la VL de la sec. con num. de ident.: 17; c) la VH de la sec. con num. de ident.: 18 y la VL de la sec. con num. de ident.: 19; d) la VH de la sec. con num. de ident.: 20 y la VL de la sec. con num. de ident.: 21. Tambien se refiere a la administracion de la cantidad terapeuticamente eficaz del anticuerpo y tratamiento de pacientes que tienen tumores solidos.
PE2017002833A 2015-06-24 2016-06-24 Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 PE20181090A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562184018P 2015-06-24 2015-06-24
US201562249546P 2015-11-02 2015-11-02
US201562250566P 2015-11-04 2015-11-04
US201562263307P 2015-12-04 2015-12-04
US201662331489P 2016-05-04 2016-05-04

Publications (1)

Publication Number Publication Date
PE20181090A1 true PE20181090A1 (es) 2018-07-09

Family

ID=57586547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002833A PE20181090A1 (es) 2015-06-24 2016-06-24 Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38

Country Status (38)

Country Link
US (1) US20160376373A1 (es)
EP (2) EP4385569A3 (es)
JP (3) JP7041519B2 (es)
KR (2) KR20240150522A (es)
CN (1) CN107921120A (es)
AU (1) AU2016281717B2 (es)
BR (1) BR112017027990A2 (es)
CA (1) CA2990620A1 (es)
CL (2) CL2017003275A1 (es)
CO (1) CO2017013332A2 (es)
DK (1) DK3313441T5 (es)
DO (1) DOP2017000305A (es)
EA (1) EA037548B1 (es)
EC (1) ECSP17084878A (es)
ES (1) ES2982292T3 (es)
FI (1) FI3313441T3 (es)
GT (1) GT201700286A (es)
HK (1) HK1254942A1 (es)
HR (1) HRP20240338T1 (es)
HU (1) HUE066300T2 (es)
IL (1) IL256248A (es)
LT (1) LT3313441T (es)
MA (1) MA71262A (es)
MD (1) MD3313441T2 (es)
MX (3) MX2018000261A (es)
MY (1) MY193727A (es)
NI (1) NI201700170A (es)
PE (1) PE20181090A1 (es)
PH (1) PH12017502311A1 (es)
PL (1) PL3313441T3 (es)
PT (1) PT3313441T (es)
RS (1) RS65347B1 (es)
SI (1) SI3313441T1 (es)
SM (1) SMT202400127T1 (es)
SV (1) SV2017005607A (es)
UA (1) UA124799C2 (es)
WO (1) WO2016210223A1 (es)
ZA (1) ZA201800476B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535355B1 (en) * 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
PT2580243T (pt) 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3122173B2 (en) 2014-03-26 2024-05-29 SCR Engineers Ltd Livestock location system
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
US11071279B2 (en) 2014-09-05 2021-07-27 Intervet Inc. Method and system for tracking health in animal populations
US10986817B2 (en) 2014-09-05 2021-04-27 Intervet Inc. Method and system for tracking health in animal populations
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
PH12017502342B1 (en) 2015-06-22 2024-01-05 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
CN114478790A (zh) * 2015-11-03 2022-05-13 詹森生物科技公司 特异性结合pd-1和tim-3的抗体及其用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
MX2019008241A (es) * 2017-01-09 2019-12-09 Biomunex Pharmaceuticals Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
CA3051113A1 (en) * 2017-01-26 2018-08-02 Sangamo Therapeutics, Inc. B-cell engineering
EP3635003A1 (en) 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
KR20250025513A (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
AU2018280868B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Limited CD38 modulating antibody
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
KR102770110B1 (ko) 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 Cd38 항체
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CA3098122A1 (en) 2018-04-22 2019-10-31 Vence, Corp. Livestock management system and method
EP3820900A1 (en) * 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) * 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
JP7451506B2 (ja) * 2018-09-27 2024-03-18 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント がんの治療用の薬学的組合せ
BR112021006730A8 (pt) 2018-10-10 2022-09-13 Scr Eng Ltd Método e dispositivo de secagem de animais de pecuária
CN113678135A (zh) 2019-02-08 2021-11-19 奥尔弗莱克斯澳大利亚有限公司 牲畜位置的判定
EP3921761B1 (en) 2019-02-08 2024-09-18 Allflex Australia Pty Ltd Electronic animal identification tag reader synchronisation
ES2988769T3 (es) 2019-02-08 2024-11-21 Allflex Australia Pty Ltd Lector electrónico de etiquetas para animales
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
JP2023510397A (ja) 2020-01-16 2023-03-13 ジェンマブ エー/エス Cd38抗体の製剤およびその使用
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
USD990063S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
IL275518B (en) 2020-06-18 2021-10-31 Scr Eng Ltd Animal tag
USD990062S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
IL275812B (en) 2020-07-01 2022-01-01 Scr Eng Ltd System and method for placing devices
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
IL302630A (en) 2020-11-25 2023-07-01 Identigen Ltd A system and method for tracing members of an animal population
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
KR20230142834A (ko) 2021-01-14 2023-10-11 모르포시스 아게 항-cd38 항체 및 이의 용도
IL280374B2 (en) 2021-01-24 2023-11-01 Scr Eng Ltd System and method for controlling animal marking
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗cd38抗體
MX2023010499A (es) 2021-03-09 2023-09-18 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cldn6.
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CA206747S (en) 2021-04-08 2024-12-30 Chevillot Sas Tag applicator for animals
CA206812S (en) 2021-04-08 2023-04-11 Chevillot Sas Tag applicator for animals
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Cd38抗體及其用途
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
KR20130135986A (ko) 2003-03-05 2013-12-11 할로자임, 아이엔씨 가용성 하이알우로니다제 당단백질 (sHASEGP), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
PT2511297E (pt) 2004-02-06 2015-08-24 Morphosys Ag Anticorpos humanos anti-cd38 e utilizações dos mesmos
EP2535355B1 (en) * 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
RS59005B1 (sr) * 2006-09-26 2019-08-30 Genmab As Anti-cd38 plus kortikosteroidi plus nekortikosteroidni hemoterapeutik za tretiranje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2342226B1 (en) 2008-09-26 2016-06-22 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3505636A1 (en) 2009-04-27 2019-07-03 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
LT2560993T (lt) 2010-04-20 2024-10-10 Genmab A/S Baltymai, kurių sudėtyje yra heterodimerinio antikūno fc, ir jų gamybos būdai
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
PT2580243T (pt) * 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
BR112013011811A2 (pt) 2010-11-05 2023-02-23 Zymeworks Inc Modelo de anticorpo heterodimérico estável com mutações no domínio fc
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
CA2873402C (en) * 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2878166A1 (en) 2012-07-24 2015-06-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
ES2621377T3 (es) * 2012-11-05 2017-07-03 Morphosys Ag Anticuerpo marcado radiactivamente y usos del mismo
WO2014178820A1 (en) 2013-04-29 2014-11-06 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
EP3021866A4 (en) * 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
EP3066125A2 (en) * 2013-11-06 2016-09-14 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
DK3313441T5 (da) 2024-10-07
HK1254942A1 (zh) 2019-08-02
CL2017003275A1 (es) 2018-04-20
HRP20240338T1 (hr) 2024-05-24
KR20240150522A (ko) 2024-10-15
PH12017502311A1 (en) 2018-06-25
CL2019003657A1 (es) 2020-05-08
MX2021012133A (es) 2021-11-03
JP2022070892A (ja) 2022-05-13
EA037548B1 (ru) 2021-04-12
JP7041519B2 (ja) 2022-03-24
WO2016210223A1 (en) 2016-12-29
MY193727A (en) 2022-10-27
ECSP17084878A (es) 2018-02-28
SI3313441T1 (sl) 2024-05-31
AU2016281717A1 (en) 2018-01-18
ES2982292T3 (es) 2024-10-15
JP2018527299A (ja) 2018-09-20
EP4385569A3 (en) 2024-09-25
GT201700286A (es) 2019-08-08
AU2016281717B2 (en) 2022-07-28
KR102713847B1 (ko) 2024-10-04
CN107921120A (zh) 2018-04-17
EA201890131A1 (ru) 2018-05-31
KR20180012864A (ko) 2018-02-06
EP3313441B1 (en) 2024-02-21
EP4385569A2 (en) 2024-06-19
RS65347B1 (sr) 2024-04-30
EP3313441A4 (en) 2019-04-24
MA71262A (fr) 2025-04-30
SV2017005607A (es) 2019-03-28
DOP2017000305A (es) 2018-04-15
FI3313441T3 (fi) 2024-03-28
MD3313441T2 (ro) 2024-08-31
CA2990620A1 (en) 2016-12-29
CO2017013332A2 (es) 2018-05-21
LT3313441T (lt) 2024-05-27
US20160376373A1 (en) 2016-12-29
NI201700170A (es) 2019-05-10
BR112017027990A2 (pt) 2018-08-28
PL3313441T3 (pl) 2024-08-19
HUE066300T2 (hu) 2024-07-28
DK3313441T3 (da) 2024-04-15
JP7532428B2 (ja) 2024-08-13
PT3313441T (pt) 2024-05-07
MX2018000261A (es) 2018-03-08
UA124799C2 (uk) 2021-11-24
ZA201800476B (en) 2021-05-26
JP2024153803A (ja) 2024-10-29
EP3313441A1 (en) 2018-05-02
IL256248A (en) 2018-02-28
MX2021012134A (es) 2021-11-03
SMT202400127T1 (it) 2024-05-14

Similar Documents

Publication Publication Date Title
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
JP2015530399A5 (es)
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
RU2015110981A (ru) Комбинации и их применение
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20190630A1 (es) Anticuerpos de anti-tim-3
MX389805B (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
JP2016520514A5 (es)
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载